# Chemotherapy Regimens

> **Evidence strength:**
> - Modified FOLFIRINOX — [Shroff et al., *JAMA Oncol.* 2019](https://pubmed.ncbi.nlm.nih.gov/31194228/) (Phase II cohort)
> - Gemcitabine + cisplatin ± durvalumab — [Oh et al., *NEJM* 2022 (TOPAZ-1)](https://pubmed.ncbi.nlm.nih.gov/35094080/)
> - FOLFOX second-line — [Lamarca et al., *Lancet Oncol.* 2021 (ABC-06)](https://pubmed.ncbi.nlm.nih.gov/33979517/)
> - CAPOX/FOLFOX adjuvant data extrapolated from [ESPAC-3](https://pubmed.ncbi.nlm.nih.gov/22382232/) and NCCN consensus

## Pick-the-plan overview

Think of chemo regimens as toolkits with different horsepower:

1. **Modified FOLFIRINOX** – the turbo engine for fit patients or clearly pancreatobiliary biology.
2. **Gemcitabine + cisplatin (± durvalumab)** – the workhorse for most biliary cancers, especially when neuropathy is a concern.
3. **Gemcitabine + nab-paclitaxel** – backup drivetrain when cisplatin is off the table.
4. **CAPOX/FOLFOX** – maintenance/adjuvant or second-line “electric motor” that runs steadier but slightly slower.
5. **Irinotecan-based options (FOLFIRI, NALIRI+5-FU/LV)** – late-line gears when oxaliplatin has maxed out.
6. **Capecitabine alone** – eco-mode for frail folks or maintenance.

### Snapshot cheat sheet

| Regimen | Best fit | Key numbers | Plain-language toxicities | Elderly tweaks |
|---------|----------|-------------|---------------------------|----------------|
| **Modified FOLFIRINOX** | Strong performance status, pancreatobiliary subtype | ORR 31–45%, PFS ~6.6 mo, OS ~15 mo | WBC drops, diarrhea, numb fingers | Start at 80%, drop bolus 5-FU, consider G-CSF |
| **Gemcitabine + cisplatin** | Default for biliary/ampullary when bilirubin under control | ORR 26%, OS 11.7 mo | Kidney strain, ringing ears, fatigue | Split cisplatin (day 1 & 8) or swap to carboplatin if CrCl <50 |
| **Gemcitabine + cisplatin + durvalumab** | Same as above but adds immune boost | OS 12.9 mo (HR 0.80) | Same chemo risks + thyroid/liver inflammation | Check thyroid/cortisol labs q6–8 wks |
| **Gemcitabine + nab-paclitaxel** | When cisplatin can’t be used or neuropathy already present | ORR ~23%, OS 8.5–11 mo | Neuropathy, low counts | Start nab-paclitaxel 100 mg/m² if baseline neuropathy |
| **CAPOX / FOLFOX** | Adjuvant post-surgery or second-line metastatic | ABC-06 OS 6.2 vs 5.3 mo vs BSC | Hand-foot, neuropathy, mouth sores | Capecitabine 1000 mg/m² bid for age ≥75 |
| **NALIRI + 5-FU/LV** | Third line when oxaliplatin spent | Disease control ~35% | Diarrhea, fatigue | 60–80% start if bilirubin high |
| **Capecitabine single-agent** | Maintenance or frail patients | Disease control 20–30% | Hand-foot, GI upset | 1000 mg/m² bid or fixed 1250 mg BID with weekly labs |

## Regimen deep dives

### Modified FOLFIRINOX = “pressure washer”
- **Why:** best shot at shrinking bulky nodes/liver lesions.
- **Care plan:** weekly CBC first cycle, neuropathy check every visit, proactive loperamide.
- **Ask the oncologist:** Will growth-factor shots be routine? What’s the oxaliplatin stop-and-go plan? How many cycles before imaging?

### Gemcitabine + cisplatin (± durvalumab) = “reliable pickup truck”
- **Why:** proven survival benefit with manageable schedule (q1–8 days, rest day 15).
- **Tips:** 1–2 L IV hydration, monitor Mg/K, dental exam before long cisplatin runs.
- **Durvalumab bonus:** immune therapy every 4 weeks—watch for thyroiditis or hepatitis, especially with stents.
- **Ask:** Can we split cisplatin over two days? What are the lab triggers to hold chemo? How do we monitor for immune side effects?

### Gemcitabine + nab-paclitaxel = “pancreatic playbook”
- Best when neuropathy risk acceptable and cisplatin is off the menu.
- Hold/ reduce if tingling or numbness creeps in; physical therapy for balance.

### CAPOX / FOLFOX = “steady cruise control”
- **Adjuvant:** capecitabine 6 months post-Whipple; FOLFOX for high-risk margins.
- **Second-line:** small but real OS bump vs best supportive care (ABC-06).
- **Home hacks:** urea-based creams day 1 onward, ice chips during oxaliplatin for neuropathy, plan rest days.

### Irinotecan-based (FOLFIRI or NALIRI + 5-FU/LV)
- Use when oxaliplatin neuropathy is limiting or intestinal subtype favors 5-FU backbone.
- Check UGT1A1*28 genotype if available; adjust if bilirubin > ULN.

### Capecitabine solo
- Good for “maintenance miles” or when combinations are too rough.
- Pair with enzyme replacement, hydration plan, and telehealth check-ins every 1–2 weeks.

## Chemo + liver-directed therapy

- Start systemic therapy first to control microscopic disease.
- Pause chemo 7 days before SBRT/Y-90 and resume 1–2 weeks after once labs stabilize.

## Supportive bundles to run alongside chemo

- **Pancreatic enzymes:** 25,000–40,000 lipase units with meals so calories stick.[3](https://www.nccn.org/guidelines)
- **Pruritus stack:** cholestyramine + hydroxyzine + cooling lotions for stent itch.
- **Vaccines:** annual flu, COVID booster, pneumococcal per CDC since chemo blunts immunity.
- **Neuropathy toolkit:** B6-free moisturizers, gentle stretching, referral to PT/OT if gait changes.

Need biomarker-driven ideas? Head to [Targeted & Immunotherapy](targeted-immunotherapy.md) next.

